Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imiquimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 15/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | HRH2 | P25021 | 1/20 | 0.82 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.82 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.82 |
| ▸ | HTR2B | P41595 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imiquimod SCHEMBL3188551 | 1.00 | TLR7 (0.82) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL5260618 | 1.00 | TLR7 (0.82) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL5262205 | 0.92 | TLR7 (0.88) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL3191041 | 0.91 | TLR7 (0.86) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL26136 | 0.91 | TLR7 (1.00) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL570774 | 0.91 | TLR7 (1.00) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL29357252 | 0.91 | TLR7 (1.00) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL3415170 | 0.90 | TLR7 (0.84) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL29029396 | 0.90 | TLR7 (0.93) | TLR7PDE4DLMNAPOLBHRH2 | |
| Imiquimod SCHEMBL17962753 | 0.90 | TLR7 (0.97) | TLR7PDE4DLMNAPOLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678912-B2 | Process for preparation of 4-amino-1-isobutyl-1H-imidazo[4,5-C]-quinoline (Imiquimod) | USV, LTD. (IN) | 2010-03-16 | — | — | US | claimed |
| US-20090209764-A1 | Process for Preparation of 4-amino-1-isobutyl-1H-Imidazo[4,5-C]-quinoline (Imiquimod) | USV LTD. (IN) | 2009-08-20 | — | — | US | claimed |
| EP-1831219-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZOÝ4,5-C¨-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2007-09-12 | — | — | EP | claimed |
| WO-2006070408-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZO[4,5-C]-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2006-07-06 | — | — | WO | claimed |
| CN-116850279-A | Reductive adjuvant nano system for relieving adaptive dermatitis and application | 浙江大学 | 2023-10-10 | — | — | CN | disclosed |
| US-7678912-B2 | Process for preparation of 4-amino-1-isobutyl-1H-imidazo[4,5-C]-quinoline (Imiquimod) | USV, LTD. (IN) | 2010-03-16 | — | — | US | disclosed |
| US-20090209764-A1 | Process for Preparation of 4-amino-1-isobutyl-1H-Imidazo[4,5-C]-quinoline (Imiquimod) | USV LTD. (IN) | 2009-08-20 | — | — | US | disclosed |
| US-20080058527-A1 | A Process for the Preparation Of 4-Amino-1-Isobutyl-1H-Imidazo[4,5-C]-Quinoline (Imiquimod) | USV LIMITED (IN) | 2008-03-06 | — | — | US | disclosed |
| EP-1831219-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZOÝ4,5-C¨-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831219-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZOÝ4,5-C¨-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006070408-B1 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZO[4,5-C]-QUINOLINE (IMIQUIMOD) | USV LTD (IN) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006070408-A3 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZO[4,5-C]-QUINOLINE (IMIQUIMOD) | USV LTD (IN) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006070408-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZO[4,5-C]-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006070408-A2 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 4-AMINO-1-ISOBUTYL-1H-IMIDAZO[4,5-C]-QUINOLINE (IMIQUIMOD) | USV LIMITED (IN) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058527-A1 | A Process for the Preparation Of 4-Amino-1-Isobutyl-1H-Imidazo[4,5-C]-Quinoline (Imiquimod) | IFNG, IRF3, IFNAR1 | TLR7 4/4885PDE4D 469/4885LMNA 2391/4885 |
| US-20090209764-A1 | Process for Preparation of 4-amino-1-isobutyl-1H-Imidazo[4,5-C]-quinoline (Imiquimod) | IFNG, IFNAR1, IRF3 | TLR7 4/4885PDE4D 529/4885LMNA 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.